Testing a new tuberculosis vaccine for people with HIV
Official title: Evaluating the safety, immunogenicity and efficacy of a robust attenuated Mtb vaccine in the setting of HIV co-infection
Funded at Texas Biomedical Research Institute · NIH-11256995 · Data updated 2026-11-12
This study is testing a new vaccine to help protect people with both tuberculosis and HIV, aiming to create a stronger and longer-lasting immune response than the current vaccine, and participants will receive the vaccine and be monitored for their health and immune reactions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Biomedical Research Institute NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | June 17, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $905,998 |
| NIH project number | 1R01AI189313-01A1 |
| Project ID | NIH-11256995 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are co-infected with HIV and at risk of developing tuberculosis.
✕Less likely to help
Patients who are not co-infected with HIV or those who have already received effective TB vaccinations may not benefit from this research.
What this research studies
This research investigates a new vaccine designed to protect against tuberculosis (TB) in individuals co-infected with HIV. The vaccine uses an attenuated form of Mycobacterium tuberculosis, which is expected to generate a stronger and longer-lasting immune response compared to the currently used Bacille Calmette-Guerin (BCG) vaccine. The study will assess the safety, immunogenicity, and efficacy of this new vaccine in a controlled setting, aiming to provide better protection for vulnerable populations. Participants may receive the vaccine and be monitored for their immune responses and overall health.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine against tuberculosis for individuals living with HIV, significantly improving their health outcomes.
How similar studies have gone: Previous research has shown promising results with similar approaches using attenuated vaccines, indicating potential for success in this novel application.
Where this research is happening
-
Texas Biomedical Research Institute
San Antonio, United States Active
Researchers
- Principal investigator: Kaushal, Deepak — Texas Biomedical Research Institute
- Study coordinator: Kaushal, Deepak
Related research
Other NIH-funded projects on the same topics.
-
Targeting human HIV latency with super-enhancer RNA targets
A short, patient-friendly plan to explore how special RNA molecules in immune cells control HIV hiding in the body and how we might disrupt that to help control the virus.
-
Pathways to trigger protective MAIT cell responses against bacterial infections
A study to figure out which bacterial metabolite antigens activate MAIT cells through MR1 to defend against TB and tularemia.
-
IL-21 therapy to boost lung immunity in HIV/TB co-infection
A study tests an IL-21-based therapy added to HIV treatment to help the lungs control TB and reduce HIV persistence in people (or animal models that simulate them).
-
Focused ultrasound to open the blood-brain barrier and reduce HIV reservoirs in the brain
A new approach uses gentle ultrasound to temporarily open the brain’s protective barrier so HIV medicines can reach the brain and shrink hidden virus reservoirs in people living with HIV.
-
Macrophage biology and metabolism in TB infection
Researchers are studying human lung macrophages to understand how they regulate immune responses and support or limit tuberculosis infection, with the goal of improving treatments that help the body fight TB.
-
Understanding how genetics and immunity shape chikungunya brain disease
A research project uses genetically diverse mice to learn why chikungunya virus causes brain inflammation in some people and how immune responses contribute to this disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.